Clinical study of CADScor system to identify non-obstructive coronary artery disease in chest pain patients gets underway

heart attack
Stock Image

Acarix has announced the initiation of a US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor system.

The focus of the study is on identifying non-obstructive coronary artery disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from emergency departments and clinics in the USA.

The clinical study will collect data from 200 patients at the University of California, Davis (Davis, USA) being assessed for chest pain in both the emergency department and outpatient cardiology clinic.

The study will assess the potential improvement in cost-effectiveness, time savings, and reduction in side effects by utilising the CADScor system to identify non-obstructive coronary artery disease in chest pain patients compared to traditional stress imaging tests.

Patient enrolment for the study will commence in early Q2 2024, marking a crucial step forward in advancing our understanding of the CADScor System in various clinical workflows in the USA the company said in a press release.

“For this study, we are evaluating the CADScor System to see if it offers patients an alternative to the standard stress test,” stated Surabhi Madwhal Atreja (University of California, Davis, Davis, USA), principal investigator of the study. “Based on the findings, this study may be foundational for rapid assessment of non-obstructive CAD, streamlining ER processes, and establishing an algorithm at UC Davis Medical Center for the safe discharge of low-risk chest pain patients, saving time and avoiding unnecessary tests and radiation hazards for our patients.”

“I am pleased to see the initiation of the first US study for the CADScor system, focused on potential efficiency improvements in the clinical and healthcare economic outcomes. This crucial step marks a significant milestone in establishing the system’s real-world relevance in the US healthcare system,” stated Acarix president & CEO Aamir Mahmood. “The study not only underscores our commitment to advancing cardiovascular care, but we also believe this study will increase awareness of the CADScor System benefits in the USA.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here